Brovana (R) (arformoterol tartrate) logo
  • Patient Medication Guide
  • Important Patient Information
  • Contact Us
  • Healthcare Professionals
  • smallmediumlarge
  • Email
  • Print
Click here to download full BROVANA Prescribing Information, including Boxed Warning.
  • About Brovana
  • What is COPD?
  • For Caregivers
  • Get BROVANA

BROVANA® (arformoterol tartrate) Inhalation Solution -- add better breathing to your daily routine

If you have COPD (chronic obstructive pulmonary disease), including chronic bronchitis and emphysema, ask your healthcare provider about BROVANA® (arformoterol tartrate), so you can breathe better. BROVANA is a long-acting medication in a fine mist that helps to relax your airways so you can breathe better.

LEARN MORE ABOUT BROVANA

Brovana for COPD | Daily Routine – Brushing I brush
Brovana for COPD | Daily Routine - My Brovana Nebulizer I nebulize
Brovana for COPD | Daily Routine – Laughing I laugh
Brovana for COPD | Daily Routine – Playing I play
Brovana for COPD | Daily Routine – Celebrating I celebrate
replay button

See BROVANA Video

Learn about COPD in this short video clip

Watch Now

Save on BROVANA

Sign up today and start saving on BROVANA

Register Now

Get COPD Information & Resources

Enjoy quick access to helpful COPD websites and downloads

Find It Here

INDICATION

BROVANA® (arformoterol tartrate) Inhalation Solution is a medicine called a long-acting beta2-agonist or LABA. BROVANA is used long term, twice a day (morning and evening), in controlling symptoms of chronic obstructive pulmonary disease (COPD) in adults with COPD. BROVANA is for inhalation use only through a standard jet nebulizer connected to an air compressor and should not be swallowed or injected.

IMPORTANT PATIENT INFORMATION

People with asthma who take long-acting beta2 adrenergic agonist (LABA) medicines such as BROVANA have an increased risk of death from asthma problems. It is not known if LABA medicines, such as BROVANA, increase the risk of death in people with COPD.

BROVANA does not relieve sudden symptoms of COPD and should not be used more than twice a day. Always have a short-acting beta2-agonist with you to treat sudden symptoms.

Get emergency medical care if breathing problems worsen quickly or you use your short-acting beta2-agonist medicine but it does not relieve your breathing problems.

Do not stop using BROVANA unless told to do so by your healthcare provider because your symptoms might get worse.

When you are using BROVANA twice a day, do not use other medicines that contain a LABA for any reason.

BROVANA should not be used in children.

Tell your doctor if you have a heart condition or high blood pressure. Some people may experience increased blood pressure, heart rate or changes in heart rhythm.

In COPD clinical trials, the five most common adverse events reported with BROVANA were pain, chest pain, back pain, diarrhea, and sinusitis. Other possible side effects include headache, tremor, nervousness, and dizziness.

For more information, please see the full Prescribing Information and Medication Guide for BROVANA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. This site is intended for U.S. residents 18 years of age and older. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

  • COPD Resources
  • get savings on brovana
  • Contact Us
  • Terms of Use
  • Privacy Statement
  • Medical Disclaimer
  • Site Map
  • Unsubscribe

BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. and prism is a registrered trademark of Dainippon Sumitomo Pharma Co. Ltd.
©2012 Sunovion Pharmaceuticals Inc. All rights reserved. 10/12 BROV085-12.